
Physician-Scientist, Oncologist, PI #MsaouelLab @MDAndersonNews | Tweets=my views | #kidneycancer #RenalMedullaryCarcinoma #endRMC #rarecancers
Houston, TX
Joined June 2017
- Tweets26.2K
- Following1.3K
- Followers3.8K
- Likes36.5K
Pinned Tweet
🚀 Now enrolling @UTMDAnderson: STaRMC trial testing sacituzumab tirumotecan in SMARCB1-deficient #RenanMedullaryCarcinoma
👉 clinicaltrials.gov/study/NCT… RMC outcomes have improved but we still lose too many. A key step to #EndRMC. #MsaouelLab #RareCancers #kidneycancer @KidneyCancer
Good luck @montypal — the ASCO team is lucky to have you!!
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Pavlos Msaouel retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Pavlos Msaouel retweeted
Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ
Pavlos Msaouel retweeted
Incredibly proud to see #TALAPRO3 led by @neerajaiims & team leading to @FDA approval! A tremendous win for #prostatecancer patients. @PCFnews @PCF_Science @DrChoueiri @PGrivasMDPhD @shilpaonc @UroDocAsh @VanitaNoronha @batraatulonc
Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU
Pavlos Msaouel retweeted
Did you know?
The original Nokia ringtone, known as the Nokia tune, is derived from a piece of solo guitar music called Gran Vals, composed by Francisco Tárrega in 1902.
Pavlos Msaouel retweeted
OpenAI has deployed a fundamental infrastructure overhaul to ChatGPT's long-term retention capabilities by introducing a dynamic, asynchronous background architecture internally designated as "dreaming." Moving away from static, user-directed text logging, this background system continuously reviews a user's entire historical conversation repository to compile an interconnected behavioral portrait.
This automated user profile is systematically structured across several distinct domains of an individual's life, seamlessly cataloging professional workflows, core hobbies, future travel itineraries, geographic locations, and stylistic interaction preferences. Because the synthesis runs continuously, it dynamically updates text metrics over time, automatically transitioning an entry from an anticipated event into a completed historical fact.
This comprehensive personalization engine rolled out first to premium subscribers, including Plus and Pro tiers within the United States, with subsequent deployments planned for Free and mobile-centric Go tiers globally. Independent analysis of this feature underscores substantial data privacy implications. In a comprehensive empirical study analyzing 2,050 synthesized memory entries from 80 real-world ChatGPT users, computer science researchers discovered that a striking 96% of all retained memories were unilaterally generated by the large language model without explicit user instruction.
28% of the compiled data blocks fell under the strict legal definitions of personal data regulated by European Union privacy statutes, while 52% of the records contained deep, inferred psychological profiles regarding the users' behavioral tendencies, motivations, and anxieties.
While developers argue that this continuous background synthesis optimizes the conversational interface by removing the need for repetitive context injection, it fundamentally shifts data-gathering agency from the user to the algorithm. To mitigate these privacy concerns, users can audit their stored profile by navigating to Settings, selecting Personalization, and opening the Memory interface.
This centralized summary menu allows individuals to manually inspect, edit, or delete specific extracted variables, or directly prompt the chatbot to disclose its current profile assumptions. Full system disabling is accessible via the triple-dot options sub-menu by selecting "Delete and turn off memory" and toggling off "Reference chat history." Crucially, removing a synthesized memory entry does not retroactively erase the raw conversation log from OpenAI's servers, necessitating that users manually delete the original chat threads. To conduct private sessions entirely outside this tracking apparatus, individuals must utilize the Temporary Chat mode, which leaves no persistent data footprint.
[OpenAI. (2026). Dreaming: Better memory for a more helpful ChatGPT. OpenAI Product Research]
[Dash, A., Das, S., Kirsten, E., Wu, Q., Karnam, S. K., Gummadi, K. P., Holz, T., Zafar, M. B., & Zannettou, S. (2026). The algorithmic self-portrait: Deconstructing memory in ChatGPT. arXiv preprint arXiv:2602.01450]
Pavlos Msaouel retweeted
What will drug discovery look like when intelligence is abundant?
Our team at @generate_biomed began with this question, and we’re excited to share some results!
We took on in vivo CAR-T and designed a scaffold 70% smaller than ones in the clinic, with 3x the potency 🧵
Pavlos Msaouel retweeted
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
Pavlos Msaouel retweeted
The largest math proof in human history is now computer-verified.
Today, Axiom announces a complete Lean auto-formalization of the Classification of Finite Simple Groups, the "periodic table of symmetry."
About 15,000 pages, built by over 100 mathematicians across generations.
Pavlos Msaouel retweeted
This is an incredible moment in this history of mathematics, computer science, physics & science with some of the hardest problems in human history being solved by AI over a period of weeks. Depending on your perspective, it's either a crisis, a triumph, or both. I don't think anyone knows for sure. We're all trying to make sense of it. I oscillate between fear/dread and optimism/excitement on a daily basis. The rate of progress is insane, including today's announcement from OpenAI of more problems solved.
To help make sense of all of it, here's my conversation with three mathematicians about this moment. Each of them is an expert in the field of each of the biggest problems solved: Navier-Stokes, quasi-Riemann hypothesis, the unique games conjecture and complexity theory more generally.
Ankur Moitra is a mathematician and theoretical computer scientist at MIT, visiting the Institute for Advanced Study in Princeton. Steven Brunton (@eigensteve) is a mathematician and fluid dynamics expert at UW. Alex Kontorovich (@AlexKontorovich) is a mathematician at Rutgers specializing in number theory.
Pavlos Msaouel retweeted
He has a point. To me the OpenAI announcement seems to be about mathematical physics.
To most people "mathematical physics" and "theoretical physics" sound interchangeable but they are different disciplines.
Theoretical physics is solidly part of physics. In this area, researchers develop either theories that explain observations already made, or they improve existing theories to make predictions for observations. (At least that's what they should be doing.)
Mathematical physics on the other hand is usually part of the department of mathematics, not physics. It is concerned, loosely speaking, with cleaning up the mess that physicists have made of their theories of nature. Or in some cases studying the properties of theories that have nothing to do with nature. (Like physics in lower or higher dimensions, fields that don't exist in nature, etc.)
People in these two disciplines work closely together of course. But mathematical physics is more maths than physics. I would not consider it part of the natural sciences as it is not itself concerned with describing nature.
I don't know exactly what the OpenAI discovery is about, but it sounds like it is more in the area of mathematical physics rather than theoretical physics. I am not saying this makes it irrelevant, but as Andreas points out, it is of limited interest for applications.
nitter.cf/karch_andreas/status/2…
Replying to @Quasilocal
Existence of Yang Mills? It’s just tying up a lose end for the hyper mathematically minded. I don’t think any physicist gives af. We have been doing precision calculations for decades. Of course it exists. But sure, would be nice to have a proof.
Pavlos Msaouel retweeted
Always great chatting with @AlexSherryMD and @JCO_ASCO on the EXTEND trial.
Hear the latest on MDT for oligomets from the first author himself, @AlexSherryMD!
Check out the paper📜 AND the podcast🎙️ for some main highlights! ☢️
📜ascopubs.org/doi/10.1200/JCO…
🎙️ascopubs.org/do/jco-article-…
@ChadTangMD @ebludmir
Pavlos Msaouel retweeted
📣 Registration Now Open for #IKCSNA26
Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America, where a multidisciplinary community of leading experts from academia, clinical care, industry and advocacy come together to share ideas, explore emerging trends and shape the future of kidney cancer research and care.
🗓️ November 19–21, 2026
📍 Dallas, Texas
🏨 Renaissance Dallas Hotel
Register 👉 kidneycancer.org/event/2026-…
@KidneyCancer @LauraBukavinaMD @QingZhangLab @bergsa83 @mkbupathi @ADESAIONCMD @AmyLuckenbaugh @virajmaster @spsutkaMD @ChadTangMD @MVossMD @TiansterZhang @PavlosMsaouel @salvolarosa @GEVaughan1
Great points @AmandaNizamMD Lenvatinib seems to provide much of the benefit. Belzutifan alone produces durable responses in a minority. Unclear to me why we should give up tolerability of belzutifan and mTORi as a MOA for ccRCC
LITESPARK-011 showed improved PFS with len + bel vs cabo in the mRCC post-ICI setting. No OS benefit yet.
Prof. Bernard Escudier with an important question: how much of the benefit is due to len itself vs addition of bel?
Similarly, we saw improvement in PFS with post-ICI len + ev vs cabo in the multicenter Ph 2 LenCabo trial from @OncHahn presented at ESMO 2025.
Sequencing in mRCC will shift as the adjuvant RCC space evolves. Congratulations to @DrDanielHeng!
@PavlosMsaouel @ChadTangMD @NazliDizman @OncoAlert @PBarataMD @ADESAIONCMD @montypal @scocmem @nataliagandur
Very happy to see these datasets rigorously dissected — onwards 🔬
Shout out to our stat Yoda @PavlosMsaouel who taught us principles of time dependent modeling!
Pavlos Msaouel retweeted
🚨📝checkout our newest #bladdercancer paper. Skin tox (🟡 on swimmers plot) common and early in EVP and linked to better outcomes in la/mUC. We also provide landmark and Simon-Makuch analyses.
🙏 stat editors @JAMANetworkOpen
🌟🥇@DrZachariahT
Co-mentor @DocMattCampbell – at Madrid, Spain
In advanced #UrothelialCarcinoma, treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer overall survival. ja.ma/4k88Qvf
Pavlos Msaouel retweeted
Incredible to see work on the very rare RCC subtypes: collecting duct & renal medullary CA at #ESMO26
#REPRINT trial testing EV + P
🎯 22% ORR & 55% DCR overall ➡️ moving to stage 2!
Also very impt trials from @PavlosMsaouel in RMC on: ubamatamab, Sac-TMT, panitumumab…
Pavlos Msaouel retweeted
Scan of a page from Erwin Schrödinger's notebook, ca 1910.
(Source: Zentralbibliothek für Physik, Vienna)
Pavlos Msaouel retweeted
At #ESMO26, researchers are exploring ways to reduce the risk of melanoma returning. Dr. Hussein Tawbi is leading UT MD Anderson’s participation in a Phase 3 clinical trial testing a personalized cancer vaccine with immunotherapy.
Learn about the research and hear about a patient’s experience on the trial: spr.ly/6013BHbvYX @HTawbi_MDPhD #EndCancer
Pavlos Msaouel retweeted
LITESPARK-011 showed improved PFS with len + bel vs cabo in the mRCC post-ICI setting. No OS benefit yet.
Prof. Bernard Escudier with an important question: how much of the benefit is due to len itself vs addition of bel?
Similarly, we saw improvement in PFS with post-ICI len + ev vs cabo in the multicenter Ph 2 LenCabo trial from @OncHahn presented at ESMO 2025.
Sequencing in mRCC will shift as the adjuvant RCC space evolves. Congratulations to @DrDanielHeng!
@PavlosMsaouel @ChadTangMD @NazliDizman @OncoAlert @PBarataMD @ADESAIONCMD @montypal @scocmem @nataliagandur
OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3







































